ImmunityBio, Inc. — Director's Dealing 2024

Jun 14, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2024-06-11

Reporting Person: BLASZYK MICHAEL D (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-11	Stock Option (right to buy)	$5.96	A	77633	Acquired	2034-06-11	Common Stock (77633)	Direct

Footnotes

F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 11, 2025 or the date immediately preceding the next annual meeting of stockholders.